Alfasigma S.p.a.
Clinical trials sponsored by Alfasigma S.p.a., explained in plain language.
-
Tracking a new arthritis Drug's Real-World performance
Disease control OngoingThis study is observing adults in France with moderate to severe rheumatoid arthritis who are starting treatment with the drug filgotinib. Researchers will follow 155 patients for two years to see how well the drug controls their disease, how safe it is, and how it affects their …
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New pill trial offers hope for chronic spinal arthritis
Disease control OngoingThis study is testing whether daily filgotinib pills can help control active axial spondyloarthritis, a chronic inflammatory disease that causes back pain and stiffness. It will compare a 200mg dose, a 100mg dose, and a placebo pill in 495 adults who haven't gotten enough relief …
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Tracking a new arthritis drug in everyday life
Disease control OngoingThis study is observing over 1,300 adults with moderate to severe rheumatoid arthritis who are starting treatment with the drug filgotinib. The goal is to see how long patients stay on the medication, how well it controls their pain and fatigue, and what side effects occur in a r…
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Drug's Real-World impact on debilitating bowel disease tracked
Disease control OngoingThis study is observing how well the drug filgotinib works and how safe it is for adults with moderate to severe ulcerative colitis in everyday medical practice. It will follow 509 patients for up to two years to see how long they stay on the treatment and if it improves their sy…
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC